Introduction: Metformin is an established first-
observational study of 45,868 patients with T2DM across 27 countries which assessed effectiveness and safety of vildagliptin as addon therapy to other OADs versus other comparator OAD combinations. Here, we present the data from Germany. reduction of [0.3% without peripheral edema, hypoglycemia, discontinuation due to a gastrointestinal event or weight gain C5%.
One secondary efficacy endpoint was the proportion of patients achieving HbA 1c \7%
without hypoglycemia and weight gain. Change in HbA 1c from baseline to study endpoint and safety were assessed.
Results: Of 8,887 patients enrolled in Germany, 6,679 received vildagliptin and 1,695 received other OADs. The mean ± SD baseline age, HbA 1c , and T2DM duration were 62.8 ± 11.0 years, 7.7 ± 1.2%, and 5.8 ± 4.9 years, respectively. 
INTRODUCTION
The prevalence of diabetes in Germany has been predicted to increase in the next two decades with about 3.9 million people aged 55-74 years affected by type 2 diabetes mellitus (T2DM) in 2030 [1] . This would result in a 79% increase in annual costs between 2010 and 2040 [2] . T2DM is a progressive disease and its longterm management warrants intensification of treatment and a patient-centric approach based on benefits and risks for the individual concerned [3] . Metformin is often recommended as the first-line treatment for patients with T2DM, but addition of other antihyperglycemic agents is usually required over time [3] . Sulfonylureas (SUs) are commonly used in patients when metformin monotherapy fails to achieve glycemic control.
However, use of SUs is associated with adverse effects such as hypoglycemia and weight gain [4] .
Vildagliptin is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycemic control by increasing a-and b-cell responsiveness to glucose. Vildagliptin as monotherapy or in combination has been shown to be weight neutral with no additional risk of hypoglycemia [5] [6] [7] . The weight neutrality and low risk of hypoglycemia with DPP-4 inhibitors has also been confirmed from a recent meta-analysis that assessed the safety and efficacy of all available second-line antihyperglycemic therapies in patients with T2DM inadequately controlled by metformin monotherapy [8] .
Pragmatic real-life observational studies are designed to provide a closer look into routine clinical practice and thus can serve as additional evidence to randomized clinical trials, which are conducted in a predefined patient population under controlled conditions [9] [10] [11] .
Effectiveness Physicians chose antidiabetic treatment for their patients at their own discretion. To avoid bias for a particular choice of treatment by the physician, enrolment of patients was agreed only after the treatment decision was made. The term 'index therapy' was used to represent the combination treatment initiated at enrolment. . AGI a-glucosidase inhibitor, ITT intention-to-treat, OAD antidiabetes drugs, SU sulphonylurea, TZD thiazolidinedione, vilda vildagliptin. *Initial (prior) monotherapy is given first within a treatment. For 12 patients in the vildagliptin cohort and 4 in the comparator cohort, it was not possible to identify the index medication For any index therapy, a fixed-dose combination, if available, was allowed. Details of the subjects and study design are reported elsewhere [12] .
Efficacy and Safety Assessments
The primary efficacy endpoint was the proportion of patients having a treatment response of HbA 1c reduction [0.3% from baseline to 12-month endpoint without peripheral edema, hypoglycemic event, discontinuation due to a gastrointestinal event, or weight gain C5%. One of the secondary efficacy endpoints was the proportion of patients achieving HbA 1c \7.0% without hypoglycemic events and weight gain C3% in patients with baseline HbA 1c C7% at 12-month endpoint (responder rate). Change in HbA 1c from baseline to 12-month endpoint (analysis not pre-specified in the protocol) and the number of hypoglycemic events were also evaluated in this post hoc analysis. Hypoglycemia was defined as presence of symptoms suggestive of hypoglycemia including mild and severe events that resolved promptly on administration of oral carbohydrate. Safety assessments including body weight, adverse events (AEs) and serious AEs (SAEs) were recorded.
Statistical Analysis
Descriptive statistics were used for these post hoc analyses. The per protocol (PP) population was a subset of the intention-to-treat (ITT) population without protocol deviation and was used for the analysis of efficacy endpoints.
Data were censored if patients changed index therapy. A binary logistic regression model was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for the probability of success in achieving the primary and secondary 
RESULTS

Patient Demographics and Baseline Characteristics
Of the 8,887 patients enrolled from Germany in the EDGE study, 513 patients (377 in the vildagliptin cohort and 124 in the comparator OAD cohort plus 12 without cohort assigned)
were excluded due to inadequate source documentation or problems with quality or accuracy of data entry. The remaining ITT population, used for baseline demographics and safety analyses, comprised patients receiving dual therapy with newly prescribed vildagliptin (n = 6,679) or a non-vildagliptin OAD added to prior monotherapy (n = 1,695) ( Table 1) . The PP population comprised 6,501 patients in the vildagliptin cohort, and 1,686 patients in the comparator OAD cohort.
The demographic and baseline characteristics of patients in the ITT population are summarized in Table 2 . After initiating combination therapy 6,439 patients (96.6% of the vildagliptin cohort) received metformin-vildagliptin and 971 patients (57.4% of the comparator OAD cohort) received metformin-SUs (Fig. 1b) .
Efficacy and Safety Assessments
The OAD oral antidiabetes drugs a The enrolled population includes all patients who gave documented informed consent b The intent-to-treat (ITT) population is a subset of the enrolled population and includes all patients who were assigned to new treatment at study start c The per protocol (PP) population is a subset of the ITT population, who completed the study without any major protocol deviation. It was used for the analyses of effectiveness endpoints CI 1.05, 1.43; p = 0.01) in favor of vildagliptin (Fig. 2) . 
DISCUSSION
The present study provides real-life data regarding the effectiveness and tolerability of vildagliptin combinations compared with other OAD combinations in patients with T2DM in Germany. The results demonstrate that vildagliptin as an add-on to other OAD monotherapy provides better glycemic control than comparator OADs, without peripheral edema, hypoglycemic events, discontinuation due to a gastrointestinal event, or weight gain
C5%.
The responder rate of HbA 1c \7.0% without hypoglycemia and weight gain observed in the present analyses is consistent with those from a post hoc analysis of data from a 2-year, randomized controlled study that compared vildagliptin 50 mg bid with glimepiride as addon to metformin [13] . In that study, the proportion of patients reaching the composite endpoint was higher in the vildagliptin-treated patients (29.8%) than glimepiride-treated patients (19.4%) [13] .
The HbA 1c drop seen in the present post hoc analysis (-0.7% with vildagliptin cohort vs.
-0.6% with comparator OAD) is comparable with the HbA 1c drop observed with vildagliptin vs. other OADs (-0.9% vs. -0.6%) in a large 6-month observational study in Germany [14] .
Current treatment guidelines recommend that it is important to avoid weight gain and hypoglycemia in addition to achieving glycemic targets [3] . The findings from the present post hoc analyses demonstrated that treatment with vildagliptin resulted in more patients achieving glycemic targets without weight gain and increased risk of hypoglycemia, which is in line with those recommendations.
Overall, vildagliptin was well tolerated and had a good safety profile. Additionally, no new safety findings or those related to any recently discussed events in a controlled, randomized setting in high-risk cardiovascular (CV) populations treated with DPP-4 inhibitors such as increased hospitalization due to congestive heart failure (CHF) [15, 16] All named authors meet the ICMJE criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. 
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